Literature DB >> 10728790

Hepatobiliary transport.

G A Kullak-Ublick1, U Beuers, G Paumgartner.   

Abstract

The alterations of hepatobiliary transport that occur in cholestasis can be divided into primary defects, such as mutations of transporter genes or acquired dysfunctions of transport systems that cause defective canalicular or cholangiocellular secretion, and secondary defects, which result from biliary obstruction. The dysfunction of distinct biliary transport systems as a primary cause of cholestasis is exemplified by the genetic defects in progressive familial intrahepatic cholestasis or by the direct inhibition of transporter gene expression by cytokines. In both, the hepatocellular accumulation of toxic cholephilic compounds causes multiple alterations of hepatocellular transporter expression. In addition, lack of specific components of bile caused by a defective transporter, as in the case of mdr2/MDR3 deficiency, unmasks the toxic potential of other components. The production of bile is critically dependent upon the coordinated regulation and function of sinusoidal and canalicular transporters, for instance of Na+-taurocholate cotransporting polypeptide (NTCP) and bile salt export pump (BSEP). Whereas the downregulation of the unidirectional sinusoidal uptake system NTCP protects the hepatocyte from further intracellular accumulation of bile salts, the relative preservation of canalicular BSEP expression serves to uphold bile salt secretion, even in complete biliary obstruction. Conversely, the strong downregulation of canalicular MRP2 (MRP, multidrug resistance protein) in cholestasis forces the hepatocyte to upregulate basolateral efflux systems such as MRP3 and MRP1, indicating an inverse regulation of basolateral and apical transporters The regulation of hepatocellular transporters in cholestasis adheres to the law of parsimony, since many of the cellular mechanisms are pivotally governed by the effect of bile salts. The discovery that bile salts are the natural ligand of the farnesoid X receptor has shown us how the major bile component is able to regulate its own enterohepatic circulation by affecting transcription of the genes critically involved in transport and metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728790     DOI: 10.1016/s0168-8278(00)80411-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Bilirubin, a curse and a boon.

Authors:  J D Ostrow; C Tiribelli
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 3.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

4.  Expression of liver plasma membrane transporters in gallstone-susceptible and gallstone-resistant mice.

Authors:  Oliver Müller; Carmen Schalla; Jürgen Scheibner; Eduard F Stange; Michael Fuchs
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

5.  Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver.

Authors:  Daniel Y Hung; Gerhard A Siebert; Ping Chang; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 6.  Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.

Authors:  Gustav Paumgartner
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

7.  Humanized UGT1 Mice, Regulation of UGT1A1, and the Role of the Intestinal Tract in Neonatal Hyperbilirubinemia and Breast Milk-Induced Jaundice.

Authors:  Shujuan Chen; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

8.  Intestinal NCoR1, a regulator of epithelial cell maturation, controls neonatal hyperbilirubinemia.

Authors:  Shujuan Chen; Wenqi Lu; Mei-Fei Yueh; Eva Rettenmeier; Miao Liu; Miles Paszek; Johan Auwerx; Ruth T Yu; Ronald M Evans; Kepeng Wang; Michael Karin; Robert H Tukey
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-06       Impact factor: 11.205

9.  Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.

Authors:  Noam Zelcer; Tohru Saeki; Ilse Bot; Annemieke Kuil; Piet Borst
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

10.  Pharmacokinetics of a novel N-methyl-D-aspartate receptor antagonist (SM-18400): identification of an N-acetylated metabolite and pre-clinical assessment of N-acetylation polymorphism.

Authors:  Masashi Yabuki; Yutaka Kon-Ya; Masaki Kataoka; Takeshi Shimizudani; Kyoko Akao; Masaki Ito; Hiroshi Kanamaru; Iwao Nakatsuka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.